Explore 3 Stock Ideas & Industry Insights Download Free Report

Announcements

Cronos Group Reports Q3 2026 Financial Results

Cronos Group Inc. filed a Form 8-K with the SEC on November 5, 2026, announcing the release of its financial results for the third quarter ended September 30, 2026.

Shwetambri Chauhan | 05 November 2026

Lucky Strike Q1 FY2027 Preliminary Results Filed Nov 5

Lucky Strike Entertainment Corporation filed an 8-K on November 5, 2026, announcing preliminary financial results for the first quarter of fiscal year 2027, which ended on September 27, 2026.

Vinay Lochav | 05 November 2026

Akebia Therapeutics Q3 2026 10-Q: 277.7M Shares Outstanding

Akebia Therapeutics, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 5, 2026, covering the fiscal quarter ended September 30, 2026.

Shwetambri Chauhan | 05 November 2026

Lucky Strike Q1 FY2027: Revenue Rises to $302.6M

Lucky Strike Entertainment Corporation filed its Form 10-Q for the quarterly period ended September 27, 2026, with the SEC on November 5, 2026, reporting total revenues of $302.6 million and a net loss of $25.7 million for the quarter.

Shwetambri Chauhan | 05 November 2026

Cabaletta Bio Files Q3 2026 10-Q With 215.7M Shares Out

Cabaletta Bio, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 5, 2026, disclosing financial and operational information as a late-stage clinical biotechnology company.

Aditi Sarkar | 05 November 2026

Arrow Electronics Q3 2026: Sales Hit $10.7 Billion

Arrow Electronics, Inc. filed its Form 10-Q with the SEC on November 5, 2026, reporting financial results for the quarterly period ended October 3, 2026, under NYSE:ARW.

Manish Choudhary | 05 November 2026

Collegium Pharmaceutical Q3 2026: Total Assets Hit $2.10B

Collegium Pharmaceutical, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 5, 2026, disclosing condensed consolidated financial statements and management discussion for the third quarter.

Vinay Lochav | 05 November 2026

Intensity Therapeutics Q3 2026: Net Loss Widens to $3.54M

Intensity Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 5, 2026, reporting a net loss of $3.544 million for the third quarter.

Manish Choudhary | 05 November 2026

Biohaven BHV-1300 Phase 3 Enrolling at 55+ Sites for Graves' Disease

Biohaven Ltd. (NYSE:BHVN) announced on November 5, 2026, continued progress in its Graves' disease program, including active enrollment in the pivotal Phase 3 trial of BHV-1300 and three scientific poster presentations at the 2026 American Thyroid Association Annual Meeting in Philadelphia, Pennsylvania.

Manish Choudhary | 05 November 2026

Kimbell Royalty Partners Q3 2026 Results Release

Kimbell Royalty Partners, LP filed a Form 8-K with the Securities and Exchange Commission on November 5, 2026, announcing the release of its third quarter 2026 financial and operating results and the posting of an updated investor presentation.

Vinay Lochav | 05 November 2026
Support

Hi! How can we help you today?

Loading…